Case Study: Boston Scientific assesses the comparative safety of pulmonary embolism treatments with Truveta Data

Boston Scientific assesses 900,000 pulmonary embolism cases with Truveta

Boston Scientific faced a challenge in assessing the comparative safety of novel pulmonary embolism treatments, as there were no randomized studies comparing them and clinical guidelines lacked modern, real-world evidence. To close these knowledge gap, they turned to Truveta and its data service.

Using Truveta Data, independent researchers conducted a comparative safety analysis. The solution provided by Truveta enabled the research team to complete their analysis, yielding key results on the safety outcomes of different treatments and generating a significant impact by informing future clinical guidelines.

Boston Scientific